How CRISPR is Revolutionizing the Treatment of Genetic Diseases

Presenter : Bertrand Sautier Guest : Jack Hopwood

The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activity around CRISPR is being measured by tracking R&D strategies and patents. You will also hear about the importance of protecting intellectual property to help accelerate the pace of innovation and minimize the risk of running into costly disputes.

To listen, click play in the built-in player below. Our podcasts can also be found on iTunes – just enter “Oncology Talks” in the search box. If you would like any information on the podcasts or if there is a topic you would like us to address, please contact us via our contact page.

All opinions expressed by the experts on this podcast series are solely the experts’ opinions and do not reflect the opinions, views, policies or positions of Clarivate Analytics or its affiliates. No one should treat any opinion expressed by the experts as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of their opinions. Experts’ opinions are based upon information they consider reliable, but neither Clarivate Analytics nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. Responsibility for the information, opinions and views expressed in podcast series lies entirely with the experts. Clarivate Analytics and its affiliates are not under any obligation to update or correct any information provided on this podcast. Experts’ statements and opinions are subject to change or removal without notice.

Previous Episode - Episode 4 Accelerating the Development of Cancer Treatment with Data Visualization
Next Episode - Episode 6 Exploring the Transformative Potential of Checkpoint Inhibitors and CAR T-Cells

Please register to access additional content

Already registered? Click here to login

About Clarivate Analytics

Clarivate Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based services focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well‐known brands that include Web of Science, Cortellis, Thomson Innovation, Derwent World Patents Index, CompuMark, MarkMonitor andTechstreet, among others. For more information, visit Clarivate.com